Immunophenotyping of male breast cancer - Experience at a tertiary care centre.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Breast Neoplasms, Male
/ classification
Carcinoma, Ductal, Breast
/ diagnosis
Humans
Immunohistochemistry
Immunophenotyping
India
Ki-67 Antigen
/ genetics
Lymphatic Metastasis
/ diagnosis
Male
Middle Aged
Neoplasm Staging
Prognosis
Receptor, ErbB-2
/ genetics
Receptors, Androgen
/ genetics
Receptors, Estrogen
/ genetics
Receptors, Progesterone
/ genetics
Tertiary Care Centers
Male breast cancer
metastasis
staging
Journal
Indian journal of pathology & microbiology
ISSN: 0974-5130
Titre abrégé: Indian J Pathol Microbiol
Pays: India
ID NLM: 7605904
Informations de publication
Date de publication:
Historique:
entrez:
12
4
2019
pubmed:
12
4
2019
medline:
3
8
2019
Statut:
ppublish
Résumé
Male breast cancers (MBCs) are uncommon and account for 1% of all breast cancers. Medical conditions that increase the estrogen to testosterone ratio are implicated as the risk factors. Morphologically similar, but MBCs have biological differences compared with female breast cancer (FBC). The present study was aimed to examine the immunophenotype of MBC, subsequent molecular subtypes, their association with clinicopathological features, and prognosis. We analyzed clinicopathological features of 42 cases of MBC, and classified them according to molecular classification using immunohistochemistry (IHC). This is the second largest study from India. Median age of patients was 61 years (age range: 41-87 years). Invasive duct carcinoma comprised 95.2% of cases. Tumor grade II and III was seen in 50% and 47.6% of cases, respectively, and advanced stage disease (III/IV) was seen in 45.2% cases (n = 39). Estrogen receptor (ER) was positive in 97.6% cases, progesterone receptor (PR) in 83.3%, androgen receptor (AR) in 76.2%, HER2 in 4.8%, Cyclin-D1 in 92.9%, Bcl2 in 66.7%, GCDFP-15 in 23.8%, p53 in 16.7%, and Ki67 index was low (<14%) in 66.7% cases. Molecular subtyping of these cases revealed 64.3% of luminal A, 35.7% of luminal B, and no HER2 rich/driven category or triple negative case. There was no statistical significance between luminal A and B category pertaining to overall stage of tumor (P = 0.905). Lymph node metastasis was more commonly associated with luminal B category (P = 0.089). p53 positivity showed significant association with luminal A cases (P = 0.002) and nodal metastasis (P = 0.042). GCDFP-15 positivity showed significant association with higher tumor grade (P = 0.042) and stage (P = 0.047). Stage was the most significant prognostic marker (P < 0.0001). On follow-up (n = 27), all the six cases that showed recurrence/persistent disease were high stage (III/IV) on presentation.
Sections du résumé
BACKGROUND
BACKGROUND
Male breast cancers (MBCs) are uncommon and account for 1% of all breast cancers. Medical conditions that increase the estrogen to testosterone ratio are implicated as the risk factors. Morphologically similar, but MBCs have biological differences compared with female breast cancer (FBC).
PURPOSE
OBJECTIVE
The present study was aimed to examine the immunophenotype of MBC, subsequent molecular subtypes, their association with clinicopathological features, and prognosis.
MATERIALS AND METHODS
METHODS
We analyzed clinicopathological features of 42 cases of MBC, and classified them according to molecular classification using immunohistochemistry (IHC). This is the second largest study from India.
RESULTS AND CONCLUSION
CONCLUSIONS
Median age of patients was 61 years (age range: 41-87 years). Invasive duct carcinoma comprised 95.2% of cases. Tumor grade II and III was seen in 50% and 47.6% of cases, respectively, and advanced stage disease (III/IV) was seen in 45.2% cases (n = 39). Estrogen receptor (ER) was positive in 97.6% cases, progesterone receptor (PR) in 83.3%, androgen receptor (AR) in 76.2%, HER2 in 4.8%, Cyclin-D1 in 92.9%, Bcl2 in 66.7%, GCDFP-15 in 23.8%, p53 in 16.7%, and Ki67 index was low (<14%) in 66.7% cases. Molecular subtyping of these cases revealed 64.3% of luminal A, 35.7% of luminal B, and no HER2 rich/driven category or triple negative case. There was no statistical significance between luminal A and B category pertaining to overall stage of tumor (P = 0.905). Lymph node metastasis was more commonly associated with luminal B category (P = 0.089). p53 positivity showed significant association with luminal A cases (P = 0.002) and nodal metastasis (P = 0.042). GCDFP-15 positivity showed significant association with higher tumor grade (P = 0.042) and stage (P = 0.047). Stage was the most significant prognostic marker (P < 0.0001). On follow-up (n = 27), all the six cases that showed recurrence/persistent disease were high stage (III/IV) on presentation.
Identifiants
pubmed: 30971545
pii: IndianJPatholMicrobiol_2019_62_2_226_255831
doi: 10.4103/IJPM.IJPM_543_18
doi:
Substances chimiques
AR protein, human
0
Biomarkers, Tumor
0
Ki-67 Antigen
0
Receptors, Androgen
0
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Pagination
226-231Déclaration de conflit d'intérêts
None